PEB's ACCUMULATED LOSSES ARE $180,000,000
That's what mighty good story telling can produce
Printable View
Good grief - sobering stuff...
As a holder I am perplexed why PEB have gone silent. Nothing at all from the new CEO - is he still on holiday or what? Those - like me - who participated in the capital raise are sitting on big losses. Fortunately I was into PEB way before that and sitting on gains overall, but I must admit my finger is hovering over the SELL button. if there isn't some positive operational news soon, I might have to assume that things are not going well and cut loose.
Not for me to tell you what to do but you must be getting a bit distraught to think about selling
Doesn't seem that long ago the share price was over $1.50 and punters fell over each other to get a slice of the cheap shares at $1.35
That's the capital markets for you
But one day you might see those 'hundreds of thousands of tests' or was it only 'tens of thousands' - can't recall what Swann said
[QUOTE=winner69;943560]Not for me to tell you what to do but you must be getting a bit distraught to think about selling
Doesn't seem that long ago the share price was over $1.50 and punters fell over each other to get a slice of the cheap shares at $1.35
That's the capital markets for you
But one day you might see those 'hundreds of thousands of tests' or was it only 'tens of thousands' - can't recall what Swann said[/QUOTE
Fortunately I still have profits that I can take - even if they are much less than they were a few months ago. :cool:
I am not ready to sell just yet, but I don't think I'd be the only one concerned at the slide in SP. It is normal for stocks such as PEB to slide in the absence of positive news, but I am surprised that there seems to be no support at any level. Of course, if all those new salespeople are actually doing what they were employed to do, then there may some good news coming and all will be forgiven. It was always going to be wild ride.
In the context of the present market, it doesn't seem so bad. Plenty of "quality" stocks out there that have shed ~20% or so recently. It's only natural for the more speculative ones to take a greater hit in these times. Diversification is where it's at.
M2C. In years gone past this company would continue to defend its share price. Never a good sign. Those days are behind us. Its a bear market ATM. Ride the wave. The market cap should reflect what the company is worth. Not always the case, but still a good guideline. Currently sitting at 785 million NZD circa 500 million USD. Any international diagnostic company would easily pay 2 Billion USD for this company. Will be interesting to see what happens over the next 6 months.
Show those international diagnstic companies some evidence of significant uptake and they just might! Pacific Edge have not, and I will counter - will not, produce $ proof any time soon. Whole lot of hope priced in and the market will come to terms with this in time.
Ha. When PEB becomes a revenue valuation model it will be worth well more then 2 billion USD. Agree that we would like to see more tests going through. But there is traction. To build the approvals and networks to date, you'd be looking at a 5 year project at a cost of more like 3 billion USD. A part of me feels this group should de-list now. There is no value in shareholder fatigue playing out, and under valuing a company like this. M&A Acquisitions in Diagnostics have never been higher on the tailwinds of Covid Testing. The big players have never had so much cash and are paying exorbitant premiums for companies like PEB. No mention of testing numbers or revenues in any of these deals. Perkin Elmer, Baxter, Fisher they are all paying premiums for these start ups pre significant revenue. But most of them are all VC backed, they know what they are in for. Traditional NZ NZX investors (institutions included) only want to back revenue investment models.
Hmm. Why wern't the big diagnostic firms buying this at 17 cents or at any time in the past couple of decades or so? I'd imagine they'd recognise potential in the science if they saw it.
It seems the tests are useful, but not (yet) sufficiently proven to be disruptive. Maybe big Pharma think they never will be?
I am not suggesting they can't or won't get there, but there is no proof yet of meaningful adoption or traction.